LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

CRISPR Therapeutics AG

Închisă

SectorSănătate

60.05 -2.72

Rezumat

Modificarea prețului

24h

Curent

Minim

59.53

Maxim

60.24

Indicatori cheie

By Trading Economics

Venit

-24M

-131M

Vânzări

-25K

864K

Marjă de profit

-15,117.245

Angajați

393

EBITDA

-48M

-149M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+16.74% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

445M

5.2B

Deschiderea anterioară

62.77

Închiderea anterioară

60.05

Sentimentul știrilor

By Acuity

24%

76%

33 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 feb. 2026, 23:53 UTC

Acțiuni populare

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb. 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 feb. 2026, 21:36 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb. 2026, 15:20 UTC

Câștiguri

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 feb. 2026, 14:43 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb. 2026, 14:38 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 feb. 2026, 13:47 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb. 2026, 13:44 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 feb. 2026, 13:14 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb. 2026, 02:32 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 feb. 2026, 02:00 UTC

Achiziții, Fuziuni, Preluări

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 feb. 2026, 02:00 UTC

Achiziții, Fuziuni, Preluări

Six Months, 9 Offers and $81 Billion. How -2-

28 feb. 2026, 00:01 UTC

Achiziții, Fuziuni, Preluări

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 feb. 2026, 23:46 UTC

Achiziții, Fuziuni, Preluări

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb. 2026, 23:33 UTC

Achiziții, Fuziuni, Preluări

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

27 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 feb. 2026, 21:30 UTC

Câștiguri

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb. 2026, 21:30 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb. 2026, 21:20 UTC

Achiziții, Fuziuni, Preluări

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb. 2026, 21:17 UTC

Câștiguri

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb. 2026, 21:10 UTC

Achiziții, Fuziuni, Preluări

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb. 2026, 21:09 UTC

Achiziții, Fuziuni, Preluări

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb. 2026, 21:00 UTC

Câștiguri

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb. 2026, 20:31 UTC

Achiziții, Fuziuni, Preluări

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb. 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb. 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb. 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 feb. 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 feb. 2026, 19:39 UTC

Câștiguri

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

16.74% sus

Prognoză pe 12 luni

Medie 70.21 USD  16.74%

Maxim 105 USD

Minim 33 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

15 ratings

10

Cumpărare

4

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

33 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat